Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 19/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090956 | 0.92 | ADORA1 (0.72) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5090387 | 0.91 | ADORA1 (0.72) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5090326 | 0.91 | ADORA1 (0.67) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5096733 | 0.87 | ADORA1 (0.72) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5096006 | 0.85 | ADORA1 (0.75) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5007774 | 0.84 | ADORA1 (0.81) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5008485 | 0.84 | ADORA1 (0.79) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5008333 | 0.84 | ADORA1 (0.79) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5089485 | 0.83 | ADORA1 (0.72) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5087424 | 0.83 | ADORA1 (0.72) | ADORA1ADORA3ADORA2BADORA2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | GPR119, IAPP, GLP1R | ADORA1 680/4885ADORA3 187/4885ADORA2B 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.